# US 2024/0197674 A1 · Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197674 A1
- Document ID: US20240197674A1
- Status: Published application
- Kind: A1
- Application number: 18/552,988
- Filed: 2022-03-10
- Published: 2024-06-20
- Earliest claimed: 2021-04-01
- Assignees: Hyundai Pharm Co., Ltd.
- Applicants: Hyundai Pharm Co., Ltd.
- Inventors: Hye Jin Yoo; Hwan Jin Hwang
- Web page: https://patentgrep.com/patent/US20240197674A1

## CPC

- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative according to the present invention promotes the expression of the myogenic factors MyoG and MyHC while inhibiting the expression of the muscle atrophy factor atrogin-1, promotes the formation of myotubes, and inhibits myocyte apoptosis, and thus can promote myogenesis and inhibit muscle atrophy.

## Claims

### Claim 1

A method for preventing or treating muscle diseases in a subject in need thereof, said method comprising administering a composition comprising a compound of Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient,
wherein the muscle disease includes one or more diseases selected from the group consisting of sarcopenia, muscular atrophy, myasthenia gravis, muscular dystrophy, myotonia, hypotonia, and muscle weakness.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound of Formula 1 promotes the expression of a myogenic factor, myogenin (MyoG) or a myosin heavy chain (MyHC).

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound of Formula 1 reduces the expression of a muscular atrophy factor, atrogin-1.

### Claim 4 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable salt of the compound of Formula 1 is a lysine salt having the structure of Formula 2 below.

### Claim 5 (depends on 4)

The method of claim 4, wherein the lysine salt having the structure of Formula 2 is characterized as having an X-ray powder diffraction pattern with four or more diffraction peaks at 2[θ] values selected from 4.61±0.2, 5.49±0.2, 6.84±0.2, 11.74±0.2, 12.05±0.2, 13.74±0.2, 16.50±0.2, 16.94±0.2, 18.45±0.2, 19.11±0.2, 20.13±0.2, 20.42±0.2, 20.87±0.2, 21.57±0.2, 23.04±0.2, and 25.02±0.2.

### Claim 6

(canceled)
